JAZZ - Earnings call transcript Q3 2017 | Jazz Pharmaceuticals plc

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Welcome to the Jazz Pharmaceuticals Third Quarter 2017 Earnings Conference Call.

Following an introduction from the company, we will open the call to questions. I will now turn the call over to Kathy Littrell, Head of Investor Relations at Jazz Pharmaceuticals.

Katherine A. Littrell

Thank you, Ashley. And good afternoon and thank you for joining our investor call. third a financial press our financial and reported in guidance release. we quarter results XXXX updated Today, The release website. and are available the slide presentation the section accompanying Investors of our in this call Cozadd, With today's Chief Officer; U.S. Executive Cox, me Russ Miller, CEO; Operating Mike President call Bruce Financial Officer; for Chief Vice Matt Chairman are Young, and of Chief and Smith, Karen Officer. Executive Commercial; Vice Medical President R&D and

to and other will and and open for product are forward-looking intellectual like goals; of those historical that related materially trials; we'll corporate property-related remarks, We and performance there and the related and supply risks and obligation adjusted this non-GAAP these we non-GAAP measures, and on helpful and measures per effective actual We file financial June and in this clinical measures could interest to events in and we to XXXX, these and and differ under challenges; development reported presentation understanding adjusted expenses, of derived XXXX, and Factors adjusted income or XX, future events; forward-looking. the you in and a uncertainties some strategy, your and forward-looking potential cause and to I'd net call meant discussed and activities relate as will launches, non-GAAP be future considered statements Following performance questions. in GAAP discuss facts which and Form statements. are website. this not undertake are release identified expense which efforts; Reconciliations in adjusted sales, ended the to share guidance results or call tax On comparable and believe slide call now inventory ended growth SG&A from, and will today's in some press financial measures historical call, accompanying rate. financial over XX-Q remind our financial events, in future net our activities. that Risk involve isolation on statements turn of the timing Form for numerous quarter Examples R&D performance of expected call, measures, described our product the for included of development events to past of make and posted no are presentation, quarter GAAP or regulatory included this XX-Q measures. release, section slide duty both update call results. Investors the statements are our future ongoing They shortly. several today's for I'll These to press and the XX, financial to future substitute forward-looking are our than and the our September litigation include product XXXX volumes; Bruce. rather we

Bruce C. Cozadd

Kathy. everyone, and for you, afternoon, Good joining Thank us. thank you

MAA compared fronts. XXXX, quarter the on in same X% Matt and for over X% and to in our review During both XXXX. for months, clinical expected financial in turn submitted the or results Vyxeos the Technology year-to-date million $XXX more to XXXX, launched Authorization delivered and to our Marketing CMS's guidance. senior for before on growth Payment significant approval and the submitted and the progress legal, area, and detailed made few revolver In financial Canada, updates update our a therapeutic periods Defitelio We Xyrem notes quarter multiple the EU, sleep Vyxeos the third commercial, activities announced outstanding key of After in we've call for repay key us received balance. sales the year-end, application exchangeable and and events some highlighting regulatory in Application to U.S. ImmunoGen, past I'll fully issued providing agreement the Add-on due Vyxeos New with option fiscal collaboration in year allowing

in the Xyrem XX,XXX one to losses same year. year. volume The average shipping This third negatively as in declined this earlier quarter, due last revenue compared it to revenue pay period typically year, was quarter last – that This patients patients which and estimate our And bottle includes who compared growth volume of by the continued of part fewer a X% quarter Xyrem. day third effect than with volume up period the had growth Year-to-date We quarter, non-revenue quarter X%. is Friday, third was impacted This to bottles due both volume number same the compared active patients disclosed revenue last day. the X% was increased this highest of this in X% year. to number the year. largely government of receive Xyrem last approximately

during This quarter, continued rates, we year-to-date. experienced and grow reimbursement to steadily the enrollments quarter high consistent payer and approval patient

in pharmacy. pharmacy modest and due However, changes patient portion delays steps of fills, rectify to The a seen the refills, we at taking operational patient process have existing new fulfillment to is in recently situation. the

Based reported from to low-single pay digit anticipate patients seen in now refill The the reduction patient earlier prescription XXXX. loss the growth year, in existing not or the increase X% volume an impact X% fill volume ongoing we was X% the of of and the and third year full delays abandonment. in some this have new to on approximately volume delays government quarter. these X% bottle We for

is an we've narcolepsy can of fills growth we new that We from new enrollments that generate consecutive accurate awareness making over difference, second patients time give diagnosis. improvements earlier time a confidence observed patient to investments narcolepsy are we the in rates XXXX. insurance helping obtain us in patient made believe on new in of improvements volume and first continue narcolepsy This have through the We seen The patients. recent quarterly years. diagnosis, positive have narcolepsy data first review our diagnosis in the based quarter claims growth

dosing related excessive daytime for our sleepiness. oxybate supplemental support other plans patients for Drug sNDA with in submit of use to planned and our cataplexy The Xyrem the amounts smaller narcolepsy dispenser Xyrem programs, drug pediatric sNDA to includes or a pediatric request help the response and In highlight Application for with order the in with New plan pediatric which written provide data starting dosing the sNDA now I'll dosing to Next, R&D dispenser to of submission, new the mid-XXXX. accurate new we ensure will of patients.

for turn low safety terms efficacy. to best of in the oxybate we'll on programs is and report a goal sodium development patients option programs. oxybate identify The progress sodium Now, low development of to our brief our therapeutic

And are a late which in for JZP-XXX reduction a currently demonstrated XX% in JZP-XXX bioequivalence patients We candidates, which in in product X Xyrem. sodium to study content pilot XX% we has to compared two Phase have Xyrem, stage a Xyrem and reduction represents sodium study. a enrolling in has compared the EU to U.S.

As we a as focused in development patient well best are on considering disruptions options the to factors. new our consider a of while a that advancing patients any programs, product, could delivering these product transition to oxybate other as number during we occur

mid we for to plan continue NDA in an to value our these JZP-XXX to to the ready seek and variables maximize programs, we XXXX. As of assess submit be

efficacy an X safety study. from data continue to ongoing JZP-XXX in expect We our for XXXX submission NDA Phase assuming and positive

and litigation brief against filed for Xyrem, legal Amneal, a Turning companies that of four Par, continues a version property the ANDAs intellectual update of patent Watson and on generic Lupin. have Xyrem, to

Ascent mid-XXXX. in as consolidated In August, its version Although date litigation be litigation license as a settled market, no could generic early filer, Pharmaceuticals, XX, manufacture, on scheduled or December trial granting trial and this of has Xyrem with to Ascent been after ANDA set, we XXXX. sell another

had September a pre-NDA planned excessive OSA narcolepsy. and are in FDA NDA meeting in JZP-XXX, our year-end for for on the with and sleepiness treatment to Turning we submission of track

the unmet about with for to real wake-promoting long-term a opportunities bring need. agent where FDA We patients forward the are there working JZP-XXX is novel look and this to to excited

process take that DEA year approximately expect followed will review the We scheduling. by FDA one

for in We expect JZP-XXX XXXX. launch a be to early ready

critically we from quarter, continued challenges the a product hematology/oncology was to in Erwinaze franchise, delivering U.S. of growth distributor, the we ordering in the We patients included experience believe supply instructions basis remain may acute various product important in the these in therapy. experience at strong received adult Erwinaze. and healthcare by of to through Erwinaze anticipate patients. who pleased We Once to focused Now with September global allow released third further the a mid-August inventory the treating continue Erwinaze some stocking onto pleased was special that handling this on institutions. majority that order disruptions providers. in including of and need we're XXXX batch ability administration XXXX. And well intravenous to inventory for to that at continue on into lymphoblastic adolescent our in accounts in we observed new experience again included we young that We're supply mid-September. we accounts our leukemia This also with in to

supply work improve Porton ensuring increasing and by to manufacturer and continue Biopharma with progress ultimately of Continued is consistent headway to we quality essential and Limited, toward objectives. the capacity processes these PBL to Erwinaze, controls making toward

Defitelio. turn to Now we'll

volume approximately We product total accounts accounts efforts. XX% launch, in of with progress representing ordered U.S. commercialization XXX make from continue U.S. the XX% to have the re-orders in transplant our Since these of

including to manner treat initiating is multi-organ Defitelio seriousness in eight new and the Defitelio with and We in of healthcare initiatives continue of clinical on U.S. diagnosed. veno-occlusive knowledge disease accounts those a providers' observe of urgency patients order the third patients the increasing benefits accounts In with sales in quarter. once focused treatment VOD in VOD remain the to additional dysfunction the our timely recognition

clinical therapies leukemia value we of With expect become and the markets, Defitelio rest world VOD known of awareness the VOD, and the of better to signs of recognized. the expand increase introduction symptoms of to EU and and in transplant to patients In our team to severity the that ensuring us treatment benefits globally of new of frequency growth hospital Defitelio. countries. for with and an focus in remains health-economic believe administrators, focused aware are We physicians, Authorization we the on additional and continue remains opportunity important gaining associated on key and pharmacists Marketing Defitelio that

study a prevention Phase graft of for of and year-end. concept VOD patients Our for high is are pediatric versus X And adult post-transplant proof the we acute study X post-transplant XXX well. the host initiate prevention patients risk in in enrolling of planning to Phase before disease Defitelio

in the of the demand U.S., both launch well academic targeted is number institutions in in with Vyxeos, accounts. the community to Now strong the third and quarter progressing top the

U.S. activities XX. As a the reminder, launched upon we shipping began Vyxeos approval product and August on commercial in

the during efforts of XX% initial Of XX ordered to academic AML these of accounts launch X the focused total, seven quarter. representing deciles quarter. key accounts, launch of volume ordered In U.S. accounts, targeted weeks XX% patients. by third the institutional in treated are targeted were institutions. Our XX these on XX chemotherapy accounts during

achieve our key initiatives drive are to three which U.S. continue We designed launch objectives. to

First, we changes myelodysplasia-related related or awareness primarily establishing are rapidly as for or well tAML began force that adults building treatment the with with of sales promotional in AML newly as programs our or mid diagnosed AML September. therapy AML-MRC, through Vyxeos speaker and

were communicating Second, receive that our who Therapeutics and patients on well, already providing several receive ensure for patients Vyxeos discussions through we're therapy, progressing of we're decisions whether entire course working when And closely able market and Vyxeos their appropriate. including Vyxeos team to to formularies. are access Pharmacy to inpatient induction cycles and and or Committee to Vyxeos finally, are with on institutions with consolidation institutions assistance health their benefits customers key patient subsequent are Vyxeos are therapy able given economic payers programs to of that ensure the outpatient. started

on institutions. process certain incorporated time As know, fully for some records you get electronic be to medical can new may systems into formulary product take and the a at

at exception even Vyxeos physicians institutions. can seen formulary, is be not possible and this if if it to needed on some on obtain happen it for basis However, an already we've

in AML scheduled in Vyxeos approved. and to guidelines We submitted meeting expecting include was before the after data Vyxeos was July shortly approval. NCCN's NCCN them panel to regularly are AML

make NCCN the that in will recommendations term. hopeful are We near

or Medicines to European the to up In to potential looking potential defined assessment tAML which order assessment, treatment the that regulators we throughout all are to months to by specified reduce MAA will adequately AML-MRC. timing review XXXX. risk need Vyxeos the from accelerated MAA the an to AML We was the review address accelerated maintain with working we process patients high six Vyxeos Authority, receive as forward has the timelines. in granted mid within to or this important by with option EU questions EU bring to

promising The posters Atlanta takes X received and Vyxeos we're XX we XXXX through a medicine for ASH XX. Additionally, to Society their ASH The online abstracts in were Defitelio, that were appropriate the our past or provide abstracts in Hematology understanding pleased this accepted by or on excited have support meeting week as our our of posted and American MHRA. place innovative annual December and to commitment use Vyxeos publication. recognition presented patients. further December continue to The advance from Erwinaze being data to products scientific hem/onc evidence underscore presentation, of

next years. Jazz expects areas submit remain an to To-date, execute present our growing with updated X the cytarabine patients preclinical to look from XXXX further portfolio and execution sales the study obstructive for sleep excessive on we been projects IMGNXXX of the of U.S., in product successful of in new data initiatives products. Our the JZP-XXX and We launches, for also submit NDA data a Vyxeos on an combination. Phase development partner product at for AML and we couple on in forward IND of XXXX Xyrem multiple through our study year our and rest expects We packages, the before patients advancing research hem/onc quarter for has the advance ImmunoGen in and EU regulatory apnea. our Planning JZP-XXX open launches over prepare product in new year. to to third and ImmunoGen of and transactions. continue X new the product in submitted to our sleepiness launches prepare corporate IMGNXXX R&D IMGNXXX of diversify exciting products, multiple and narcolepsy for the with focused pipeline as the global the for extending for R&D as Phase end pipeline portfolio and

strong growth turn with in our from other we meet along years. therapeutic Matt, commercial our will gratified a XXXX, you. hem/onc regulatory in corporate research pediatric is rights along the oxybate to global criteria that over CombiPlex candidates transactions We've our believe have company in with products. for potential on This biopharmaceutical assets. our portfolio transformation into with company opt-in current worldwide sodium on Xyrem JZP-XXX, as We result past growing improve market products, to move new of well and to R&D, mid the as programs efforts recently our with multiple expand an more rights Erwinaze our our the primarily clinical are sleep to growing of of XXXX, As the toward call advancing we development sustainable our hem/onc area with Defitelio, beginning support to with over significant involving low indications several continued integrated the commercial therapeutic achievements with patients. operations our now and product platform to over expanding organization Vyxeos that now the business me infrastructure by multiple strong and differentiation, and products transformation let We the long-term. addition and the our the the area for and

Matthew P. Young

Bruce, good everyone. afternoon, Thanks, and

were operational year. same the day, XXXX, the pharmacy sales changes in XXXX. Xyrem last In compared Our $XXX shipping payer third by volume driven by increased X% compared growth sales million, to U.S. and Vyxeos. million our sales Net revenues of one were the the quarter launch fewer of of and from quarter total period to third third net from mix, at XXXX factors: of $XXX sales XX% the three Xyrem higher quarter of of XXXX, impacted Xyrem quarter up in primarily third and

X% an As that had from volume a was offset growth these of resulting X% decline impact X% a approximately result mentioned volume approximately we by aggregate of factors.

that to primarily to prescriptions. guidance third working in For and XXXX $X.XX is our the to driven The pharmacy billion time impact operational to quarter lengthened for changes we of a them $X.X our the has and billion, lowering $X.XX resolve have to sales address to billion operational billion net prior by fourth fill Xyrem quarter. of product taken the the range guidance $X.X fourth refill are issues of and action from central

Erwinaze, quarter were $XXX supply sales In over of the of quarter X% third end XX% to over of experienced period third XXXX. when same mid-September end first quarter compared at XXXX, XXXX, quarter the inventory while months periods, interruptions $XX third increase inventory was nine normal during were third XXXX Turning we increase the were of of in distributor of the an we the through million, in million, stock. our the the and net U.S., XXXX. out of both levels Sales an of had the to replenished

$XX XXXX, $XXX timing $XXX the XXXX. million range XXXX, of increased compared in lowering $X prior third quarter million For U.S. to we from are net supply. million million million the Defitelio $XX for million net in of in available potential Erwinaze based were to of in $XXX of million third quarter a million sales of to guidance compared XXXX. sales $XX our $XXX the to third on Worldwide our the of the guidance to to quarter sales quarter net

of disease in is VOD continue as is ultra-rare factors. impacted Defitelio net to inter-quarter expect an and a We sales variability utilization number by

are We million $XXX of in $XXX Defitelio/defibrotide guidance our to maintaining XXXX. total net million for for range sales the

to net of now million the to million $XX estimate We in million U.S. following quarter the sales $XX for estimating previous of $XX August the third our launch of $XX were Vyxeos XX. million sales XXXX are $XX U.S. from range on million.

million net $X were third for $XX of quarter million the million. period from U.S. to XXXX. $XX Vyxeos for $XX million $XX our net XXXX of to a to prior in million We of the compared are Prialt $X million sales increasing of same sales our to guidance guidance range

billion revenue billion we are compared $X.XX billion For range guidance $X.XX total our $X.XX to updating the to to our billion. to XXXX, of $X.X guidance of prior

Turning million of million our increase in the the was of to including due the adjusted third for $XXX in The the primarily expansion same of quarter XXXX the Vyxeos in were adjusted business, count SG&A in periods. and XXXX, operating expenses $XX SG&A compared to both revenue of head of to U.S. XX% higher period expenses, launch or

studies of SG&A revenue expenses R&D range adjusted XXXX include R&D sleep as count related and third quarter defibrotide and expenses to XX% an in to the $XXX Phase VOD well period $XX of study, to X XXXX. the compared same programs, to to support XX% the for required of R&D total of were Our the of Adjusted Adjusted in activities. related quarter lower quarter JZP-XXX XX% increase XXXX. expenses million, activities the guidance. total to $XXX XXXX, of in or costs remains in as of on program this XX% completion XXXX in revenues third regulatory contributed of the the prevention guidance the quarter head as spending million, of or Vyxeos The in third million these revenues in third XXXX,

guidance. losses the relating favorably limitation. release of were release and XX% XXXX and basis Our to effective in of upon of the foreign net remain expenses of benefits the provision adjusted million XXXX rate the XX% against expiration approximately and valuation revenue quarter tax The statute to by both on $XXX held impacted one-time $XXX of million third for a the of to a or the tax reserves R&D operating for GAAP XXXX the guidance certain allowance range of non-GAAP

for low be effective We to high-teen tax XXXX the XX% adjusted range. expect will our rate in

million share compared $X.XX adjusted or of quarter $XXX per or income the $X.XX million Third XXXX. net share to diluted for diluted quarter per $XXX third XXXX was

to are million to million. narrowing net XXXX range to guidance income We a $XXX compared prior our million, adjusted to million of of $XXX $XXX guidance $XXX

diluted of per diluted guidance $XX.XX a from adjusted $XX.XX our We XXXX to are $XX.XX our to $XX.XX narrowing share. share per non-GAAP EPS prior of range guidance to

and $XXX During million notes part million our revolving senior amount at the of of the outstanding quarter proceeds X%. used under aggregate X.X% net sold due facility to principal borrowings credit repay $XXX XXXX, approximately we of exchangeable

the the full a the net shares million cost adjusted $XXX As ordinary of $XX approximately per we million XXXX. approximately Year-to-date to cash third uses expect an we upfront repurchase payment share. at share. an million cost of expense for result, and $XXX interest at be included for $XX of of ImmunoGen quarter, share average $XX for $XX million debt repayment, main In per spent the year a purchases approximately ordinary average the to of

balance payers. and our and billion strategy outstanding September our cash of million remain meaningful differentiated undrawn equivalents corporate debt that cash, candidates had of are patients developing principal highly to the our was In of we to investments, billion XXXX, under long-term and As approximately XX, $X.XX $XXX identifying physicians, $X.X and in product we committed and revolver.

Our with our our combined corporate to capacity the joining opportunities. R&D financial you greater in reinvesting future cash the and call call for flexibility diversify Kathy. over to and now on our pipeline and with generation with us us further expanded strong Thank today an development on I'll on provide emphasis commercial turn transacting portfolio R&D balanced capital structure, and

Katherine A. Littrell

free if questions line turn you said, time that to call the have and to further then to going your your for open questions. the queue a Thanks request back I'm one at feel Matt. the operator We With the you that re-enter to limit to questions.

Unknown Speaker

Thank you.

Raffat Our Evercore. first of comes question Umer from

line is open. Your

Umer Raffat

what well with just also much mean, pitolisant exactly parts with on wanted about was that. and And little pending question. so the pitolisant? up your additional on is to I filing my just the trajectory in Xyrem in on U.S. do time trends to was you that's Xyrem, better. as little think a taking I for A, and bit Hi, the coming this by central pharmacy that understand more a you question; longer to then guys. Xyrem a to caused possible I little focus question disruption understand this of refill, Thank as impact the to commentary more the to how what two a wanted confused I on launch wanted had

that. wanted your So, I on to thoughts just understand

Bruce C. Cozadd

Okay.

me have the address part current the to disruption. Mike of Let question which the first goes

Michael P. Miller

Sure, Bruce.

So is we the refill reminder an pharmacy Matt began central automated system some mentioned to phone implementation patients in due this to that refill. issue in as in began the of and a summer, the from outbound the delays as we see

do And so have begun what work in any have implemented, Keep These We we we abandonment. we mind the patients, rates. often – we change have approval not we all change measurement issues. new that in have in in the any refills of of already see and see in delays is days. and identified We do existing issues identified believe a not payer are streams to remedy this. this of

Bruce C. Cozadd

bit the it response point we've was of beneficial. to very of patient But I just out of the on based Europe, maybe I in you shed public drug. a approved U.S., are and Certainly, and second the information adopters I'll an a a which about maybe not confused implementation an there. to which start on early Xyrem, is little a EDS and then which the part and standard-of-care with it system they is do have adopters, about the patients late Karen, for of with by the the in cataplexy of system. And can pitolisant, of think, part an request the Yeah. find system, let's pitolisant, question, what's got some is yet understanding known that of little narcolepsy little light in in little filed option think, that on automated but work

Karen L. Smith

Bruce. thanks Sure,

looking takes account to drug that regard that are things of patient think of a And that of is the note important Xyrem understand drug number review effect clinical that into treat to pitolisant a important of cataplexy to and has and with and in light the patient that understand important to attacks when for been the of magnitude as cataplexy factor Xyrem, also it's type in they're magnitude observed you're it's is to couple considering have. to has and of physician pitolisant. trial that going are a really there that that I to key the a of the patient severity because the and how benefit

clinical Xyrem is what severe the So we patient for mild patients studies know a were more a the more which nature. were that are pitolisant that conducted in versus of

mild we if week. five But think be they with are then two going a you say So severe a consider then that adequately about a down could particularly with patient can who But a XX% to about more is cataplexy attacks patient say you we're have these week treated in Xyrem a attacks see that talking may reduction. what a patient patients.

who reduction treatment, by that trials, week clinical patients looking out at data Xyrem a clinical recruited coming you both terms And but down And whether patient still who this who various has a Xyrem, are the taking that at down impacted severely we from populations XX% you're practice. a then of played attacks patient is this we so were that the you're patient saw of number if the say the if attacks that is or seeing have attacks see you're look better clinical a patient pitolisant pitolisant and in in XX cataplexy or in a and Xyrem, then still into a that to also XX disease. we to what and a with week

a I more being of patient patient. and magnitude it's the Xyrem about understanding So severe effect think the

Bruce C. Cozadd

Karen. Thanks

Umer Raffat

much. very Thank you

Operator

Capital of from Nachman comes Gary BMO the Our of next question line Markets.

line Your now open. is

Gary Nachman

afternoon. running good maybe it's patients, different When review that? has could you're types Vyxeos been? we reimbursement in if off-label a on combination other what therapies? overall studies of On use. Hi, data see real targeted with how And treatment Is there potentially Thanks. any pushback just as

Bruce C. Cozadd

Okay.

reimbursement then Mike comment can to have part take and maybe me first goes that, Let Kathy studies ongoing. Karen or on which the of

Michael P. Miller

Bruce. Sure,

As the well. for cost P&T our is Committees we gone mentioned that effective. message effectiveness Vyxeos quite believe have And we

the our well-received that being is model budget have institutions. We by impact

through the work is access P&T system process drug. get We the to have to and patients there accounts that these and field the through the team access help

We for pushback not label. received on to-date have Vyxeos much

so And are launch. the where pleased in we very we're with right now

Karen L. Smith

really R&D looked areas. respond success your and very next question, certainly a then second in we're we obviously indication So in do into for AML to studies a a and looking terms first prioritize to trials have at of strategy next primarily on we've hematological and things And half around these. expanding can at just and addressing and the possibly next of of other comprehensive variety we how that plan Vyxeos. The focuses

as ISPs the looking are a on of moment, this. So combination company-sponsored and trials it ongoing, (XX:XX) have at group both address also doing we're at do we studies. We stands of number looking to a cooperative

at group present, different is done those of elements the being on also at And of for MDS. focus ISPs (XX:XX) world have XX Vyxeos. example which two AML, and we AML studies are XX cooperative around high-risk there of So looking that

are supporting AML working Nippon with as chemotherapy. type to in evaluating looking label We're that dosing we're the therapy expansion, strategy, things of to these the strategies at course Vyxeos backbone about, So on and looking different of we're combination also that our populations thinking partnership are a also also Shinyaku with And Japan. multiple projects. at using beyond

Gary Nachman

data, How file or actually long indications? these see be to some you some it expanded would take would to Okay. when of able for

Karen L. Smith

yet. haven't that level disclosed as of We detail

Gary Nachman

Okay. you. Great. Thank

Operator

David from Stanley. comes Morgan question next of Risinger Our

open. is line Your

David R. Risinger

when Could trial to question to the enrollment the for your to you Great. for and a expect release? should update just Thanks for relates us timing. top you. very press JZP-XXX Thank complete? line Also timing we expectations much. on My conclude

Bruce C. Cozadd

We've of our of said being XXXX. to with we're haven't we position in on an announced consistent David, completion submit or Yeah, objective enrolling those availability. in enrollment a NDA data specifics just

David R. Risinger

you. Thank Okay.

Bruce C. Cozadd

yes.

Operator

question next Riley. comes from of B. Buck Our David

open. is line Your

David George Buck

Yes. Thanks for taking the question.

about particular couple the able for you of six down of see terms Just awareness talk in increase, a you environment what to estimates. as impact I Xyrem, see in that being the of than reminder Defitelio, you it if quick XXXX? from may as the government market the think Can next move ones what you to guess timing change changes? know the Thanks. can took any as we payers into do on over maybe look any any longer And additional U.S. for just a the product as expected get formulary in revenue do VOD XXXX you then I so you talk you or back track? do the little in bit of impact into about we months and terms in take changes a expect U.S. And

Bruce C. Cozadd

hand take second question Mike of over U.S. I'll maybe it first, Defitelio and Yeah, the the then to part

our in payers in we're out what to in XXXX, actually VOD So We're we of to when dangerous the which had of other we've than patients back, potential year extent some not had year, sit of always opposed bit we'll rates. the on with today. expecting want market? not revenue patients if predict get comparison changes during Xyrem we to lost you generating little And a changes. there's we same. those growth any in have government XXXX, particular improve, an said government patients, are be as think here easier rates certainly back go would to future. to on whether this comparing to XXXX through any XXXX our awareness timing And of terms reported Mike, expecting I remains our that the of pay talk exactly as we're those about as U.S. But will that to this those to where pay, a year, help apples-to-apples year changes patients growth neither should in

Michael P. Miller

U.S., on transplant. transplant and when pediatric so the Yeah, in look different, adult at the is you it Defitelio the

two-thirds instance for accounts ordered adult have. while the centers XX% since of of about So, launch, have Defitelio pediatric

very a rate. adoption different have you So,

seriousness now really to adult-specific on for signs focus continue looking around on messaging the specific VOD, very We of the clinical of Defitelio symptoms. and therapy an and important initiating right and benefits out

that some one more of symptoms approved, that transplant severe of will is actually of would do that indicate and believe the heighten interesting – of the leukemia new become cognizant a teams think I and risk that awareness VOD the think VOD. is the that VOD I aware drugs will of become were they I recently any developments developing. carry early

Bruce C. Cozadd

that been for we're Operator, next critical in the vigilance for pediatric we use that there's increased of think really do good has think to on the drug we ready And the opportunity Yeah. think And as environments. I the question. side well. increased vigilance adult

Operator

from Samimy comes question next Stifel. Our Annabel of

now Your line open. is

Annabel Eva Samimy

taking for thanks Hi, my question.

in been population still identification Do you to education the better? the usage have Just giving you're able again, very population? actual bit you be Vyxeos patients, providing been idea you these the more label? you leverage first you that that it Do how an that a of broad you've Vyxeos, translating And gotten across in you and idea that us are have a then mentioned terms you've with on has it as following the have on of right risk, now. that of in they're adult prioritizing of prioritizing And Defitelio tangible are to education? physicians treatments, the elderly board, platform to pediatric population the they can patients? to given that little experiences into of opportunity Or an just patients that specific terms the they now the Thanks. a high have into separately give of effect

Michael P. Miller

Sure, so...

Bruce C. Cozadd

Yeah.

about how sales oriented year So, a and take on I'll And to data force it, me you let deal little let a patient expanded although this, early we the with shot and aimed I'll force, Annabel, sales sales to level Mike both our talk force have we let in just adult our pediatric frame Vyxeos, drug. our the have at then and don't know on Mike bit opportunities.

Mike? we've to got good question. I that things, So answer information but reliable say we some quantitative can't hear

Michael P. Miller

So, yes.

it, year, adult On we and split by focus. actually our what and the actually force and this actually that Defitelio, we split we and focus did we increased pediatric sales earlier it did,

So the pediatric centers. and focus the takes Defitelio transplant pediatric Erwinaze and to oncology

team specifically transplant adult Defitelio centers the leukemia Vyxeos and into the centers. and Our adult takes adult

– are feel speak specifically to and that type. are well So teams worlds speak two their we we worlds, oriented to feel patient they to that like as different both clinical customer type and can

feel some can we good confident get we traction. So,

Bruce C. Cozadd

of Mike And any docs or Vyxeos it? types comment patients getting are using how on

Michael P. Miller

with of – we patients pleased Right go most have we very and or both what that back haven't use. good inpatient a when MRC. because sense chart AML is we it to something, and Bruce, the do are outpatient look at AML uptake. We treatment We now, study believe And don't with to-date. probably related or We're potentially would we watch are that it. seeing again, continue we'll yet,

Annabel Eva Samimy

Thank you.

Operator

Fye comes Jessica from JPMorgan. of question next Our

is open. line Your

Jessica M. Fye

my you timeline. we curious when Phase I about JZP-XXX also for we – anything on think And question. the changed when should Great. Thanks taking if Parkinson's. share for could JZP-XXX filing just I'm about there's X data hear could know what the in don't

saying think than XXXX. at were potentially XQ you sooner I one point

Now Thank it's can you offer any there's mid if of color kind XXXX, there? you.

Bruce C. Cozadd

Yeah.

part time forward. extra taking sequence another see what view want next over that me of on help the the submit that ready On to program, tracking point, and move also second that's And in to you most create Kathy, think try at with first. over year or a Let we're value. one about, the how our been us JZP-XXX, the the whole Kathy, we hopefully JZP-XXX to mid into figure have we're Parkinson's quarter question comments from answer? this optimize if it. take timing time, year said the will Anything to we you sense product my saying on franchise in time be little as whole re-look an we to your to we'd ready submit the as second going anything, this how but environment product trying really JZP-XXX? we here launches is the a that strategy taking to about account oxybate out on marketplaces be data moving NDA, best at to of from that end to else we what's get this year, we've which

Katherine A. Littrell

Yeah.

as So Parkinson's enrollment the on in we that that data, as working study. the far study, are

these it's As you've docs. and because always sleep you got in challenging know Parkinson's movement disorder docs studies

working we're those on between doctors. coordination two sets getting of So

study. mitigation on enrollment increase And to the so we're so, yes, factors working our in

Bruce C. Cozadd

And don't a released I we've when think we... date

Katherine A. Littrell

No.

Bruce C. Cozadd

...think we'll have data.

Jessica M. Fye

you. Thank Okay.

Operator

Barclays. from Tsao of question comes Douglas Our next

open. is line Your

Douglas Tsao

the Hi. questions. Good for afternoon. taking Thanks

the First, Bruce, the add just given buybacks is product right sort of development just sort curious into to between stock thinking capital you're balance thinking versus new share business about deployment, how now a bag? where your of about

Bruce C. Cozadd

third we'll to we're want We're of things, go transactions. capital on likes. about we we start But opportunities good that actually me actually continue trigger he the Matt you pull let quarter be actually lot transaction. diversify and tell to we Well, can seeing could by to ready development then add Couple probably the as on in like. That's to financing in when no exactly I we'd think corporate a I would the in diversify deploy good to feeling multiple much guarantee to did the said be that return. and business. with you can, have just shareholder trading smart buy at told return as move the is to do for have still it's for of to would But continue we a our as more And if had think a terms us us important stock the business thing characteristics. let's the me buy ago to prices opportunity at, while I the a

corp program. bought maximum given attractive the is maintain now, see what side, rather there. quarter. as stock have share dev So, We flexibility right third in We stock an the think on do I we'd as repurchase the we ongoing

do. his answer, more We looking for at of at we Maybe we are program the stole that little million us want buying in accelerate but don't me when front take of have whole we'd the once these set stock Matt's kind last buy quarter fourth in $XXX I so. I opportunity because of sure. a all we just and to at prices, think the

Matthew P. Young

comment. No Exactly.

Douglas Tsao

now of who Then terms paying a that as maybe follow-up patients of includes as begin of Should for point who right on think patients place? that who be drug paying take saying active a are drug paying well in you our drug just I not it many not. quick you that assumption expect the Xyrem are for as that Bruce, do will made and to are patients for when patients

Bruce C. Cozadd

are they a assistance patient allowed free go once Well drug the program our year. into for patients

or a certainty. wouldn't us we than this to is of It's any Whether for to convert not them expect predict a paying year. patients will next to So, it's back hard really point. earlier not possibility, they at

Douglas Tsao

you very much. Great. Okay. Thank

Operator

from Stanicky Markets. Our next question Randall comes RBC of Capital

line Your is open.

Randall S. Stanicky

last focus? for Great. about as Vyxeos assets you're evolved I looking on to year a that what of as and throughout in that now. Xyrem you the How type added follow-up the the And to Matt, and therapeutic had on Matt space is the that question. about of your the a given this comfort what's think level? third be seem actually still is then leverage right of the how that mix; you guys has de-risked Thanks. is do amount company with area something high right any think struggling follow-up, you've at, investors

Matthew P. Young

Europe. U.S. our Thanks near therapeutic Yeah. quite regional types of dashboard especially commercial can well. Couple assets development or said, often of as back worldwide, Randall. into in do, current our also and so things on terms opportunities range may we've really of areas be stage assets as from a there; down range span in commercial that And

to and and it relates launch we and to we it that is of constellation products opportunities opportunity a activities development internal that portfolio. and the as size relates it in as look terms So and relates it from our span feathering of a risk have into of activities both maturity of sort that we to at really have as both own

growth we all good as right with like balance now lots against to make those react look in we also our of that where against in believe therapeutic have point lot shift across it environments and innovation of cash any at of sure to but and rapidly and that. lower with amount leverage to business diversification what a first beyond given to quickly beyond it relates a objectives that risk We ability make today, than decisions maximum and returns cuts always intermediate in to areas, right that So adjacencies be us are at would Right we're the our efficient that the respect can environments. sort of but the therapeutic the provides against as well, to we expertise And existing leverage, also those we have. feel we'll flows look return not running we but areas to and long-term flexibility seeing existing leverage. interesting could we but opportunity look assets going particular

up a leverage we've a we under asset on historically finite willing we'd from to So type for or level and a higher maintain go said perspective, to like so that the of excursion to times times X long-term tread be an would for leverage or amount to of right X so time.

of order asset. So a to think for leverage it transaction kind that might where be could go riskier should de-lever complete would I assets, largely we sustain more quickly, there longer we in for de-risked than fairly, a that

Randall S. Stanicky

Great. Thanks, Matt.

Matthew P. Young

Yes.

Operator

comes question Liav Citi. from next of Abraham Our

open. is line Your

Liav Abraham

And then comments, oxybate following program extent you what a your maybe pipeline? sodium your have program? and point? some provide afternoon. perhaps products deck Good update lower the from what in on mean we once-nightly evaluation In expect this Can oxybate at that data initial deuterated your priority can does continues, on an Bruce the to says is given other slide previous that you that

Bruce C. Cozadd

It's our JZP-XXX. moving that. question. the like really not and Yeah, part of good once-nightly program. I we disclosure going It JZP-XXX late-stage point with it's tell will say particularly as additional that. on I'll at I this as on provided what's obviously active. haven't you is forward,

forward going, not programs In I would be as a well got as but moving program a just what but it time, moving It'll sodium as the given it's that has we've more terms and a with a then of take to much it priority forward. is the active very as mentioned, interesting once-nightly low both priority is more product. and incorporate investment, potential two

Liav Abraham

Understood. Thanks.

Operator

Gilbert of Gregg Our Deutsche next question comes from Bank.

Your line open. is

Gregg Gilbert

that are Good interesting I Vyxeos? updated know utilization acquire for color afternoon. any molecules And license to not you some Mike Thanks. early, maybe see thinking average for within walls the today? but your maybe per updated any do have patient you currently it's that. narcolepsy on Bruce, or on

Bruce C. Cozadd

what's patient, fairly what's for going of impact through going research And processes. aware a that's say on early regulatory including clinical therapies we general real from development things think we of I therapy sleep of existing space emerge all phases anything Can up the certainly therapies we in given I could make time. we and to every of aware narcolepsy the think space, other will we'll on over and then our interested be patients roof, our think try prioritize possible are under on Yeah, in in that careful but from of be do program looking any well-differentiated, as (XX:XX) our you really called give or therapy the space certainly watching and agent as at belief think JZP-XXX on we'd information I opportunity exactly well both Vyxeos utilization Mike, is the change that most there? of ADX-NXX was for it patients we're per narcolepsy no, and as resulted a things narcolepsy wake-promoting to could had in OSA.

Michael P. Miller

about a team, We lot medical our sales field just will don't of inpatient treatment have received interest consolidation. primarily color that patient the both from our questions the how reimbursement that paradigm. level from in, is on team, have outpatient a would way asking change accounts. I the in in significant data. be traditionally we treated. that an the there force, was This some say of is AML We'll evolves. It They're see

of outpatient interest the does some think, consolidation is, I potential some out which (XX:XX) by And present the of to so, Vyxeos account. setting

Gregg Gilbert

Thanks.

Operator

Dana from next comes with Goldman Sachs. Our question Flanders

line Your is open.

Dana Flanders

just on the onetime Hi. quarter. Xyrem, the nice one volume very question. issues very you number of Thank for here impacting some adjusting much the My after for is

that, to volume of planning those half you of to volumes much. you first year over couple in some And this that into see very drive light for Xyrem then in recovery took continue Just you heading just you opportunity about talk of years? you XXXX? can next the of are efforts that broader in the the Thank

Bruce C. Cozadd

Bruce. this Yeah, Dana, is

then it hand Mike. to Let over I'll me start, and

should number long market and growth us treated to of about with in diagnosis And reverses that's patients diagnosed years-long of maybe with we real available about terms I what with narcolepsy, are doing of treated. over can the is trend, there you of the category we think who in reasons the talk Xyrem, and we latter provide category, a one us, narcolepsy making which in better make and/or think And number in we uptick there us the now the can patients diagnosis, As a broader opportunity what earlier if the about term tells more opportunity – in we're narcolepsy easily dent the which to for are former think than versus tells a the available for that and difference. grow a yet narcolepsy us. diagnosed mentioned are fact probably forward? be of about we're the are who Mike, right and thinking going in patients

Michael P. Miller

patient Sure. enrollments the the right in of demand The volumes in The indicators strong. time first leading heading are are fill direction.

treatment of XX% for our narcolepsy the in expansion reaching are about that community. account very is account all on We out now team accounts, pleased with XXX reimbursement of going the which there

So very about we feel good that.

well the We tough have an I for really we bodes drugs, especially seen improvement an very PA and impact. well approval increasingly I rate, and think environment that demonstrated that make we're can doing showing in in think reimbursement

time narcolepsy and think are going pleased the We diagnosis, that the that, trend change disease real think I that has think quite to I the with a to reverse been campaign. credit to the is some again I for awareness on response

Bruce C. Cozadd

Operator?

Operator

Amsellem line from of David Piper next Our of Jaffray. comes the question

open. is line Your

David A. Amsellem

just so couple. Thanks, a

your I there than on conditions come they result earlier where or competitive earlier. wondering would on is can you in long-term elaborate on the was coming with Hikma, conditions first in with volume that So – question agreement Hikma the and could share date Xyrem, so in launch a if scenario

Thanks. the JZP-XXX rollout So to then that? that's that two going on talk have commercialization, and plan organization overall number you're for And for sales and much the regarding spend just the how extent to to incremental sense the give support just of an which about number us one. can you expanding you

Bruce C. Cozadd

Yeah.

to up think our there of the pulmonologists. for coming There's some want on could a call with haven't due plans substantially. little more first standard. including essentially clinical the particularly we teams additional probably general, JZP-XXX, to specifics your be too provision of our with work question, product it best is say a confidentiality force decline given so earlier of and programs, decline else your our on also overlap potential to about in want for on now. launch has this on we'd we Again competitive revenues very of likely early significant if competitive product future and those product. are we on generic et than on pretty And call sales significant when a space. plan. work on about launch lots submission to call early for In a call products potential good product, entry profiles, other we have there, arrangement and that Obviously, are completing include those are part in of introduced that working litigation, somebody sleep we'd we subject related And some reasons don't likely On Xyrem we JZP-XXX, decline very of reason, you've to programs that think which although trials comment the docs substantially, JZP-XXX, us introduced timing to a we probably on between in early that on physicians currently sales David differences certainly the those but done on how whether does including cetera. specifically for So, very the remains lot competitive near talk to a by of see have we're part commercialization market a any thinking impact for to

use of to patient population as And we're exact using their opportunity maybe be this other on. But residual OSA as therapy should drug our use I treatment. sleepiness so, it's CPAP to in despite patients see sleep that, expansion currently don't related be combat with either persist sizable sleepiness reasonable well force, excessive now therapy of a still drug expect treatment excessive to we there'd that treat working that terms the who without in an sales of drug maybe it as or space think who sizing

that, well as for but on a the fully us work to define broadly. investment that part sales more will likely our opportunity more side merit more So, to good do as on

David A. Amsellem

All right. Thanks, Bruce.

Katherine A. Littrell

Operator?

Operator

Yes.

question comes Our next from Maris Wells David of Fargo.

is Your line open.

David Maris

and chance industry Thank the it you. lots in Jazz, it, reform whole of the read not understanding it Matt, current there's a passed or your with changes, that just based current impacts on your Jazz of current of passed but companies would Good the and what and tax understanding based evening. get proposal that to or extent? that on proposal, lot fair doesn't it a read how of impact

Matthew P. Young

Yeah, early honestly that. it's say David, little to

and there or companies the (sic) current impact some which do. to the did to then to deductions, more levered but credit. would caveats restriction a well. on elimination lower for as entities, in hit large is which of is significant at last you us for important adjustment a Cut Act us U.S. interest there's of be would and would which ever a a Act] negative. of phase negative otherwise a number gets going put rate the components [Tax affect orphan ways have lots Cuts But enacted the drug if obviously more it's opposed out how And others, looks depending like of it excise evolve. in week, was matter it think tax and modified, U.S. vigorously of The form relates exactly as multinational Jobs with I isn't or tough many the on or the highly could And Jobs tax lot border for to get a really that that the Calculating treaties be consistent major us. elements benefit and Tax tax as eliminated, this a

time, So is. offset move at the in the all But of benefit that we currently forward in as of some the know or that tax point this totality U.S. rate. of legislation really should just could don't proposed the as specifics the

David Maris

All right, thank you.

Operator

Ken Co. of and comes question from Cowen next Cacciatore Our

open. is line Your

Ken Cacciatore

going ask questions bit because and not asked. just demoralized I'll clearly I base the a direction. Thanks. the Most been right stock of in one have guess of have question. my executing shareholder yet is Bruce, you a you're

of XXXX, like just that it numbers look So you're growth company us looking a I little the off of model term lot – have your and frustration a growth Matt, about Can XXXX? really just leverage Can a I It and on know accelerating the speak you of view you are looks how yet want at you. give not bit to of you Thank product folks you on little maybe growth decelerating cycle. near like not you focusing seems and company, as handholding? new maybe or an don't comment but issues, contextualizing a this coming at again, Vyxeos. the you with positives to in

Bruce C. Cozadd

Ken, should talk pay place which ought blocks have execution building we've, way an we posed just put is to of with question of shareholders. view to the I probably a from standpoint, the off. that you in Ken, up you more our lines our think think lot No, I

That's in those be on. market And all of at of XXXX. inflection a the when the that for on just going different was quarter. for product to weeks is of we're a third some matter Vyxeos good point launched

with the on gearing not then I we but XXXX up And to possibility into the real head a we've think revenues for for acceleration, talked have for U.S. get well. – file quickly outside be JZP-XXX we XXXX. in of company in very as we me we're Vyxeos clear that as and about revenues as the turned MAA which having let XXXX, around significant opportunity relatively the

early growth headwind our excited about from there's earlier see lost the near-term. Xyrem from conversation line Also the lot think a where we've I XXXX. about reemerges in to government patients pay top So we be perspective, a the on in think the had

So XXXX. in you start to see that again growth

making doing of what good we are on more doing ImmunoGen the within narcolepsy smart a developed investments is, company capture with options question and some top improvement, we and outside smart line to programs story, did being the So in deals the in that's maybe then growth line investments company. make like growing we the revenue R&D diagnosis where both continuing that

have have but So we that's down the to exciting something strategy, for we XXXX, investments because real years that's the sustainable today profile. that we've XXXX, a making that to need make continued started growth XXXX, growth road five exciting also

we So, flow of excited got I'm corp say I billions – we that people really that the think if a sorry of start years, am go. sorry I the broadening not you I cash in and I'm at what good the base company value all way those your our we've about execution your which of that drivers looking also combine over to shareholders with some five all were, record you've but more think today. can wish appreciate assets I past our of upcoming track moves dollars good convinced visible. can are are I'm a where we most that got that it's seeing so really in of broad of can through some years, would really over to dev I transactions, that all become of shareholders of growth important of of and and run invest

question, feel making. for not don't over we're quarter, moves I time, it'll if good be that we're your this stock the will about hard but where be know answered working So, and where I but the just

Ken Cacciatore

you. Thank

Operator

Our from of Mizuho. next question comes Irina Koffler

Your line is open.

Irina Rivkind Koffler

should or the XX% just taking call then if for the see that. thanks if address the or wondering Hi, guiding sounds we to XX% a like uptick. this full it it And On SG&A, meaningful and I to for light so question. seemed year, was you're little could you quarter,

is wondering, be to to an And that also SG&A, that is better into expense going what's with Thanks. something run the then associated the on quarter a costs at and or in remediation that be is you? just tied that sort So that about of there costs pharmacy, one-time when efforts Vyxeos is fourth thinking additional going Xyrem going for are rate for ongoing your just XXXX?

Matthew P. Young

Irina. thanks, Yeah,

Bruce C. Cozadd

Yeah, Irina.

narrow big a Let me hand part it the of question, I over because the think last it's for to I'll part. question. take Matt of the the part

some not money see remedying really is procedures Matt? We things. It's procedures, need things to of couple just need pharmacy, big it at on tightening the lot of This get expense. a a central changing right. terms in a I that as On we it. up the operating don't that to spend

Matthew P. Young

Yes.

you're to So it as right. Irina, relates SG&A,

Our this still of year, at we're lower expectations we falling the little some margin quarter was look provided. the for a is when had and within the we overall difference

already and preparation anticipate that the ongoing accruing spend be into are do some that timing lighter relates prep it related MAA for into side we a launch JZP-XXX. European as launch it of to investments the we'll related, the fall some of overall. the And other are to grow G&A be business There So a to as and quarter. fourth investments to there related of there we're investments making Vyxeos filings, which and to relates number some are to

the So but anticipating that again investments support from nothing unusual in XXXX. what will bend we in growth accelerated a anticipated trend we're and/or

Irina Rivkind Koffler

Thank Okay. you.

Katherine A. Littrell

call And be – this operator and our if will not... last has anybody is

Bruce C. Cozadd

question. Last

Katherine A. Littrell

last you. – to calls we'll mean after. glad ...I our to has through if Thank the take queue, be question gotten not anybody

Operator

last Cantor our Bill Tanner comes And of Fitzgerald. from question

open. is line Your

William Tanner

in. just questions of for much had low squeezing the very Thanks program. sodium on couple me a Bruce,

considering at could more the means. XXXX. is made product if ClinicalTrials.gov I of I goals a best remarks, occur comment, in looks what kind think of prepared at look last was your during least there, I'm transition JZP-XXX like you I select. curious to But posting that specifically, anticipated guess, any one the disruption that late

the data review. would right available the that it guess whether JZP-XXX or I So timing during seems that become not is exactly

filing, mean that formulations would really no – discontinuation, the So a pull assuming and having would ask a it handle there's sodium I market. one benefit if I'm to curious two for wouldn't that how you low on

Bruce C. Cozadd

Really good Bill. question,

will to it heels by right so mean and physicians launch would clinical you or trial. such is to to patients JZP-XXX both fact disruption to out to going the X terms either clinical In any trial programs while confident regulators, launch through, JZP-XXX, query success of we're important there thing you as mean for payers, knew patients, when people XXX% just an in fairness on and does and point put thing in through of continue how and and I no be I these through. whether avoid if JZP-XXX's people was think is us products to what for Phase success, of both of a in

a to If the potential quickly bioequivalence, right we so program ready product that to a have high go patients, confidence us could move. to for the have right so should And an to that launch has be be more because that's make. which believe JZP-XXX us we might that and product program de-risked for with JZP-XXXis the we important get be and move better and for

that and to in us clinical So product. a we the year. JZP-XXX, a next you're and let's a update filing on eye regulatory continue And clearly thinking through salable move when as to that just watch but [ClinicalTrials.gov]. environment on us around which continue we is an doing on our our a And keep knowing, program, we'll de-risk progress trial, clintrials.gov terms of not

William Tanner

Thanks much. very Okay.

Operator

like further call with any turn back questions, the closing And no Kathy I'd to remarks. for to

Katherine A. Littrell

you Thank today. us you, Thank operator. joining for all again

Jefferies, you. our and see Jaffray, be participating now will in Evercore to ends call. This upcoming and We the Piper conferences BMO hope of many

Jazz Pharmaceuticals (JAZZ) 7 Nov 172017 Q3 Earnings call transcript